UCSF

UC San Francisco Previously Published Works

Title

Inactivating mutations in Drosha mediate vascular abnormalities similar to hereditary hemorrhagic telangiectasia.

Permalink

<https://escholarship.org/uc/item/1mh2x7w0>

Journal

Science signaling, 11(513)

ISSN

1945-0877

Authors

Jiang, Xuan
Wooderchak-Donahue, Whitney L
McDonald, Jamie
et al.

Publication Date

2018

DOI

10.1126/scisignal.aan6831

Peer reviewed

VASCULAR BIOLOGY

Inactivating mutations in Drosha mediate vascular abnormalities similar to hereditary hemorrhagic telangiectasia

Xuan Jiang,^{1*} Whitney L. Woolderchak-Donahue,^{2,3*} Jamie McDonald,³ Prajakta Ghatpande,¹ Mai Baalbaki,¹ Melissa Sandoval,¹ Daniel Hart,^{1,4} Hilary Clay,¹ Shaun Coughlin,¹ Giorgio Lagna,¹ Pinar Bayrak-Toydemir,^{2,3†} Akiko Hata^{1,4†}

The transforming growth factor- β (TGF- β) and bone morphogenetic protein (BMP) family of cytokines critically regulates vascular morphogenesis and homeostasis. Impairment of TGF- β or BMP signaling leads to heritable vascular disorders, including hereditary hemorrhagic telangiectasia (HHT). Drosha, a key enzyme for microRNA (miRNA) biogenesis, also regulates the TGF- β and BMP pathway through interaction with Smads and their joint control of gene expression through miRNAs. We report that mice lacking *Drosha* in the vascular endothelium developed a vascular phenotype resembling HHT that included dilated and disorganized vasculature, arteriovenous fistulae, and hemorrhages. Exome sequencing of HHT patients who lacked known pathogenic mutations revealed an overrepresentation of rare nonsynonymous variants of *DROSHA*. Two of these *DROSHA* variants (P100L and R279L) did not interact with Smads and were partially catalytically active. In zebrafish, expression of these mutants or morpholino-directed knockdown of *Drosha* resulted in angiogenesis defects and abnormal vascular permeability. Together, our studies point to an essential role of Drosha in vascular development and the maintenance of vascular integrity, and reveal a previously unappreciated link between Drosha dysfunction and HHT.

INTRODUCTION

Vascular morphogenesis and homeostasis are controlled by various signaling molecules, such as vascular endothelial growth factor, ephrin, fibroblast growth factor, Notch and Delta-like 4, and angiopoietin (1). It has been increasingly evident that signaling mediated by the transforming growth factor- β (TGF- β) family of cytokines [TGF- β s and bone morphogenetic proteins (BMPs)] is essential for regulating vascular development and function (1). TGF- β and BMPs bind to cell surface heterotetrameric type I and type II receptor complexes, which are transmembrane dual-specificity kinases. Upon ligand binding, the type I receptor kinase is activated and phosphorylates Smad proteins, which then bind with co-Smad Smad4 and translocate to the nucleus and bind DNA and modulate gene transcription (2). Alternatively, Smad proteins are incorporated into the Drosha microprocessor complex through association with p68 (also known as DDX5) and DGCR8 and promote the production of a subset of microRNAs (miRNAs), which, in turn, target various mRNAs (3). Drosha, a ribonuclease (RNase) III enzyme, cleaves the primary transcripts of miRNAs (pri-miRNAs) to generate precursor miRNAs (pre-miRNAs) in the nucleus. Pre-miRNAs subsequently give rise to mature miRNAs of ~22 nucleotides (nt), which are noncoding RNAs that regulate gene expression by directing target mRNAs toward degradation or translational repression (4). Drosha is essential for the biogenesis of nearly all miRNAs, with the exception of a few intronic miRNAs (5–10). In addition, Drosha has functions other than gene regulation. For example, Drosha directly associates

with a hairpin structure within target mRNAs, leading to their cleavage and degradation (11, 12). Drosha also associates with the promoter-proximal regions of genes and regulates their transcription (13).

Deregulation of the TGF- β or BMP signaling pathway causes hereditary hemorrhagic telangiectasia (HHT; MIM187300), a vascular disease also known as Rendu-Osler-Weber syndrome (MIM600376) (1). HHT is an autosomal dominant disease with aberrant vascular development that occurs in ~1 in 5000 to 8000 individuals (14). The characteristic lesions found in patients with HHT include epistaxis (nosebleeds) and dilated and often tortuous blood vessels that lack a normal capillary bed between artery and vein (14). Clinical manifestations of HHT include recurrent epistaxis; telangiectasias of the lips, hands, and mucosa of the nose and gastrointestinal (GI) tract; and arteriovenous malformations (AVMs) in the lung, liver, and central nervous system (15). In general, the development of vascular lesions in HHT is associated with abnormalities in the development and function of endothelial cells (16). Therefore, understanding the link between the TGF- β signaling pathway and endothelial cell homeostasis is critical to uncover the molecular etiology of HHT.

Causal mutations for HHT have been reported to occur within genes encoding components of the TGF- β signaling pathway, such as the ligand (BMP9, also known as GDF2), receptors (endoglin and activin A type II-like 1, also known as ALK1), and signal transducer (Smad4) of the TGF- β and BMP pathways (17). Most HHT mutations in these genes are thought to be inactivating mutations (18). Endoglin and Alk1 are predominantly found in endothelial cells. In particular, Alk1 binds preferentially to BMP9 and BMP10 and plays a critical role in endothelial cell homeostasis and function (18, 19). Only BMP10, however, is present during embryonic development in mouse (20). Collectively, the genetic evidence suggests that HHT is caused by the impairment of the TGF- β or BMP pathways in endothelial cells.

In the present study, biochemical analyses revealed that the missense mutations Pro¹⁰⁰→Leu (P100L) and Arg²⁷⁹→Leu (R279L) in the N terminus

¹Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94143, USA. ²Associated Regional and University Pathologists Institute for Clinical and Experimental Pathology, Salt Lake City, UT 84108, USA. ³Department of Pathology, University of Utah, Salt Lake City, UT 84108, USA. ⁴Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94143, USA.

*These authors contributed equally to this work.

†Corresponding author. Email: pinar.bayrak-toydemir@aruplab.com (P.B.-T.); akiko.hata@ucsf.edu (A.H.)

of DROSHA had partial loss of function that resulted in a markedly reduced interaction with Smads upon BMP4 treatment. Furthermore, *Drosha*-deficient zebrafish showed abnormalities in vascular development, and mice with an endothelial-specific knockout of *Drosha* exhibited disorganized, dilated vasculature and hemorrhage, which resemble the clinical presentations of HHT patients. Finally, we found an overrepresentation of missense variants of *DROSHA* in HHT patients compared to the control population. These observations suggest an essential role of *Drosha* in the development and homeostasis of the endothelium and suggest that a hypomorphic *DROSHA* allele might be linked to the pathogenesis of HHT.

RESULTS

Drosha morphants show vascular abnormalities

To study the function of *Drosha* during vascular development, two different morpholino antisense oligonucleotides (MO1 and MO2) against *Drosha* were injected into transgenic [*Tg(flk1:egfp)*^{s843}; *Tg(gata1:dsRed)*^{sd2}] zebrafish (*Danio rerio*) embryos at the one- to two-cell stage to knock down *Drosha* expression (hereafter called “*Drosha* morphants”). In this transgenic fish, enhanced green fluorescence protein (EGFP) labels endothelial cells and dsRed labels hematopoietic cells (21). MO1 targets the translation initiation (ATG) and MO2 targets a splicing site. At 1 ng of MOs, the gross morphology and blood circulation of *Drosha* morphants were normal, except for the development of a mild pericardial edema (Fig. 1A, bright-field images). No abnormalities in vasculogenesis were detected in *Drosha* morphants; however, ~40% of the intersegmental vessels (ISVs) of the trunk, which are among the first vessels to form, were prematurely truncated in ~90% *Drosha* morphants (Fig. 1A), and vascular density was decreased (Fig. 1A). Coinjection of in vitro-transcribed human *DROSHA* mRNA, but not control RNA, rescued the vascular phenotypes in *Drosha* morphants (fig. S1, A and B), further supporting the idea that the phenotype of *Drosha* morphants was due to depletion of *Drosha*. Furthermore, all *Drosha* morphants displayed underdeveloped cranial vessels (fig. S1C). To quantitate the ISV phenotype, *Drosha* or control MO was injected into the *Tg(fli1:nEGFP)*⁷ zebrafish, which expresses EGFP in the nuclei of all endothelial cells (21) to allow counting of cell numbers (Fig. 1B). The anterior, middle, and posterior region of ISVs contained 45% less endothelial cells on average in *Drosha* morphants compared to control MO-injected zebrafish (Fig. 1B), indicating early angiogenesis defects in *Drosha* morphants.

To further examine the phenotype in the absence of *Drosha*, clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 genome editing was applied to transgenic [*Tg(flk1:egfp)*^{s843}; *Tg(gata1:dsRed)*^{sd2}] zebrafish (*D. rerio*) to generate genetic *Drosha* null zebrafish, and several *Drosha* mutant lines were established (fig. S2A). One of the mutant lines in which 4 nt in exon 2 of the *Drosha* gene was deleted, resulting in a frameshift mutation at asparagine (N) 40 of *Drosha* and premature termination (hereafter referred to as N40fs), was used for subsequent analysis (fig. S2, A and B). Upon mating N40fs heterozygous mutant (N40fs/+) fish (F3), which developed normally and had normal life spans, N40fs homozygous mutant (N40fs/N40fs) fish were produced in Mendelian ratios and exhibited no developmental abnormalities or angiogenesis defects up to 3 days postfertilization (dpf) (fig. S2C). At 10 dpf, however, N40fs/N40fs fish exhibited a developmental delay (fig. S2D), and all N40fs/N40fs fish died between 14 and 16 dpf, similar to *Dicer1* knockout fish (22). At 3 dpf, the amount of *Drosha* mRNA in N40fs/N40fs fish was indistinguishable from N40fs/+

and control (+/+) fish (fig. S2E). This was due to the persistent expression of maternal *Drosha* after the maternal-to-zygotic transition. Furthermore, miRNA abundance in N40fs/N40fs fish at 3 dpf was unchanged from control (+/+) fish (fig. S2E). However, at 10 dpf, *Drosha* mRNA abundance in N40fs/N40fs fish was 50% of the littermate controls (fig. S2E). Consistent with the reduction of *Drosha*, all miRNAs examined were significantly reduced in N40fs/N40fs fish compared to the littermate controls at 10 dpf (fig. S2E). In *Drosha* morphants injected with MO1 and MO2, however, the depletion of miRNAs was evident as early as 3 dpf (fig. S2F) because MOs target both maternal and zygotic *Drosha* mRNA. Although the phenotype of *Drosha* morphants should be confirmed by generating the maternal-zygotic mutant of *Drosha* in which maternally derived *Drosha* is ablated by the germline replacement technique to exclude the possibility of off-target effects of MOs (23), *Dicer* maternal-zygotic mutants exhibit vascular defects similar to *Drosha* morphants (24). Thus, we examined *Drosha* morphants to assess the effect of the depletion of *Drosha* and miRNAs on developmental angiogenesis.

To examine vascular permeability in *Drosha* morphants, fluorescein isothiocyanate (FITC)-conjugated dextrans (diameter, ~10 nm) were injected into the caudal plexus at 54 hours postfertilization (hpf). Twenty to thirty minutes after the injection, the surface of both anterior and posterior ISVs was marked by FITC-dextrans in control *Tg(flk1:egfp)*^{s843} zebrafish, indicating a normal vasculature (Fig. 1C, control MO; FITC-dextran). In *Drosha* morphants, however, the surface of ISVs and caudal veins appeared rough, indicating leakage of FITC from vasculature (Fig. 1C, white arrows). The intensity of FITC-dextran signal in the caudal plexus area of *Drosha* morphants was 1.9-fold higher than that in control MO-injected fish, indicating a higher permeability of the vasculature in *Drosha* morphants resulting in rapid accumulation of FITC-dextran in the caudal plexus area (Fig. 1C, right). At 45 min after injection, FITC-dextran signal was nearly undetectable in the vasculature of *Drosha* morphants. In contrast, FITC-dextran signal was detectable in the control zebrafish (fig. S3). However, when polymer microspheres (diameter, ~25 nm), which are larger than dextrans and cannot easily leak from the vasculature, were injected into *Drosha* morphants, the microspheres remained in the vasculature for up to 2 hours, suggesting a lack of gross defects in the vascular wall in *Drosha* morphants (Fig. 1C, left). Thus, we conclude that the depletion of *Drosha* in zebrafish produces an increased vascular permeability.

Endothelial cell-specific deletion of *Drosha* in mice results in vascular defects similar to HHT

To examine the role of *Drosha* in the development and homeostasis of endothelium in mammals, an endothelial cell-specific *Drosha* knockout mouse (*Drosha* cKO^{EC}) was generated by crossing a *Drosha*-floxed (*Drosha*^{fl/fl}) mouse (25) with a *Cdh5-Cre* transgenic mouse line (26). *Cre* recombinase in the *Cdh5-Cre* mouse is expressed specifically in CD31⁺ (a pan-endothelial marker) endothelial cells in the yolk sac since as early as embryonic day (E) 7.5 (26). To determine whether recombination was successful and resulted in depletion of *Drosha* in endothelial cells, total RNA was prepared from CD31⁺CD45⁺ cells isolated from E11.5 embryos by flow cytometry and subjected to quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis. *Drosha* mRNA in endothelial cells from cKO^{EC} embryos was reduced to 33% of that in control littermates (*Drosha*^{fl/fl}, *Drosha*^{fl/+}, or *Drosha*^{fl/+}; *Cdh5-Cre*⁺) (fig. S4A), demonstrating efficient deletion of *Drosha* in endothelial cells. Vasculogenesis and angiogenesis appeared superficially normal in *Drosha* cKO^{EC} embryos; however, all cKO^{EC} embryos died around E14.5 to E15.5 due to a hematopoiesis defect (27).

Fig. 1. *Droscha* morphants exhibit vascular abnormalities with increased vascular permeability. (A) Two different *Droscha* morpholino oligonucleotides (MO) (MO1 or MO2) or control MO (Ctrl) were injected into *Tg(flk1:egfp)^{s843}*, *Tg(gata1:dsRed)^{s2}* zebrafish at the one- to two-cell stage. Representative images of intersegmental vessel (ISV) are shown. $n = 33$ zebrafish for Ctrl MO, 34 zebrafish for MO1, and 35 zebrafish MO2. The fraction (%) of fish with defective ISVs and vascular density are shown as means $\pm$ SEM. White arrow, defective ISVs. $^{**}P < 0.01$, $^{***}P < 0.001$, $^{****}P < 0.0001$, significant by one-way analysis of variance (ANOVA) with post hoc Tukey's test. (B and C) Ctrl MO (2 ng) or *Droscha* MO (1 ng of MO1 + 1 ng of MO2) was injected into *Tg(fli1:nEGFP)^{y7}* (B) or *Tg(flk1:egfp)^{s843}* (C) zebrafish at the one- to two-cell stage. (B) Representative images of the anterior (A), middle (M), or posterior (P) regions of the ISVs. The number of endothelial cells (ECs) per ISV was shown as means $\pm$ SEM. $n = 33$ zebrafish for Ctrl MO and 28 zebrafish for *Droscha* MO. (C) Representative angiography images of ISVs and the caudal plexus are shown. Mean fluorescence density of the caudal plexus is presented as means $\pm$ SEM. $n = 18$ zebrafish for Ctrl MO and 20 for *Droscha* MO. a.u., arbitrary units. $^{*}P < 0.05$, $^{**}P < 0.01$, $^{***}P < 0.001$, significant by two-tailed unpaired Student's *t* test. Scale bars (A to C), 200 μ m.

Immunofluorescence staining of the endothelial marker CD31 showed that branching of blood vessels was reduced by 20% in the yolk sacs of cKO^{EC} embryos at E13.5 compared to those of control embryos (fig. S4B), suggesting that early endothelial patterning was mildly affected by *Droscha*

deletion. Whole-mount CD31 staining revealed twisted, disorganized, and dilated vasculature in the liver of cKO^{EC} embryos at E12.5 (Fig. 2A). Consistently, CD31 staining of E13.5 liver sections revealed tortuous, disorganized blood vessels only in cKO^{EC} embryos (fig. S4C). Hematoxylin and eosin (H&E) staining of E14.5 liver sections in cKO^{EC} embryos revealed the presence of erythrocytes in the extravascular area, which is evidence of vascular leakage (fig. S4D, circles). Furthermore, immunofluorescence staining for zonula occludens-1 (ZO-1), an essential component of tight junctions, was weak or undetectable in the liver vasculature in cKO^{EC} embryos (fig. S4E, circles). This result indicates a disruption of the endothelial barrier and increased permeability of blood vessels in the fetal liver and is consistent with vascular leakage observed in the liver sections from cKO^{EC} embryos (fig. S4D, circles) (28). Dorsal aortas (DAs) in cKO^{EC} embryos were also dilated: 41.6% larger than littermate controls at E12.5 (Fig. 2B) and 52.9% larger by E14.5 (Fig. 2C), indicating a progression of DA dilation during cKO^{EC} embryonic development. 5-Ethynyl-2'-deoxyuridine (EdU) staining did not reveal differences in the proliferation rate of endothelial cells from cKO^{EC} or control mice (fig. S5A), suggesting that the DA dilation in cKO^{EC} mice was not due to increased endothelial cell numbers. Similar vascular abnormalities were found in the extraembryonic vasculature of cKO^{EC} embryos, such as tortuous vasculature (fig. S5B), misalignment of artery and vein in the yolk sac (fig. S5C), and dilated umbilical arteries (fig. S5D). These results further support an essential role of *Droscha*-dependent miRNAs in the control of endothelial homeostasis and alignment of arteries and veins.

To examine *Droscha* function during postnatal vascular development, a tamoxifen-inducible endothelial-specific *Droscha* knockout (*Droscha* iKO^{EC}) mouse (*Droscha^{fllox/fllox}*, *Cdh5-cre/ERT2⁺*) was generated by crossing the *Cdh5-cre/ERT2* transgenic mouse line (29) with *Droscha^{fl/fl}* mice. Tamoxifen was injected at postnatal day (P) 2 and P4 to induce the excision of the *Droscha* gene in endothelial cells. *Droscha* iKO^{EC} mice were viable, had a normal life span, and

had no substantial differences in gross morphology compared to tamoxifen-injected littermate controls (fig. S6A). Immunofluorescence staining indicated that *Droscha* protein had been successfully depleted in endothelial cells in iKO^{EC} mice (fig. S6B). qRT-PCR analysis confirmed

Fig. 2. Depletion of Drosha in the endothelium in mice results in embryonic developmental vascular abnormalities similar to HHT. (A) Representative images of a whole-mount liver from control (Ctrl) or *Drosha* cKO^{EC} embryos at embryonic day (E) 12.5 stained with CD31 are shown. Quantitative analysis of the diameter of fetal liver capillaries is shown as means ± SEM. Scale bar, 100 μm. *n* = 4 Ctrl embryos and 3 cKO^{EC} embryos. (B) β-Galactosidase staining was performed to visualize the dorsal aorta (DA) isolated from Ctrl or cKO^{EC} embryo at E12.5. Quantitative analysis of the DA diameter is shown as means ± SEM. ****P* < 0.001, significant by two-tailed unpaired Student's *t* test. Scale bar, 50 μm. *n* = 4 Ctrl embryos and 4 cKO^{EC} embryos. (C) Representative hematoxylin and eosin (H&E) stain images of a 7-μm transverse thoracic section of Ctrl or cKO^{EC} embryos at E14.5. Scale bar, 100 μm. The diameter of DA was quantified by ImageJ and presented as means ± SEM. *n* = 3 Ctrl embryos and 3 cKO^{EC} embryos. **P* < 0.05, significant by two-tailed unpaired Student's *t* test. Hemorrhagic telangiectasia, HHT.

reductions in *Drosha* mRNA and miRNAs in endothelial cells sorted from the livers of iKO^{EC} mice (fig. S6C). Casting analysis showed dilated capillaries in the lungs and livers of iKO^{EC} mice (Fig. 3, A to C). The distal capillaries of lung and liver exhibited bulges and roughness (30), suggesting increased vascular permeability in iKO^{EC} mice compared to Ctrl mice (Fig. 3, A and B). No AVMs or arteriovenous fistulas were detected in the lungs (Fig. 3A) or livers (Fig. 3B) of iKO^{EC} or Ctrl mice. Similar to the yolk sac vasculature of cKO^{EC} mice (fig. S5C), the arteries and veins in the GI tract of iKO^{EC} mice were misaligned, unlike those in control mice, which ran in parallel (Fig. 3D, top). In addition, the feces from iKO^{EC} mice appeared darker than those from control mice (Fig. 3D, bottom). A fecal blood test validated the presence of blood in the feces of iKO^{EC} but not of control mice (fig. S6D). Together with the disruption of tight junctions in the intestinal vasculature (fig. S7B, ZO-1 staining, white arrows), these results suggest that the presence of blood in the feces of iKO^{EC} mice is due to intestinal bleeding, a phenotype also exhibited by endothelial cell-specific *Alk1* knockout (*Alk1*^{fl/fl}; *L1-cre*) mice (30). Casting analysis of the subcutaneous vasculature in iKO^{EC} mice was not possible when the blue casting agent was injected from the left ventricle, because it did not flow through the veins. Therefore, the veins remained red, whereas the arteries turned blue in control mice (Fig. 3E, Ctrl). However, the casting agent could flow from artery to vein in ~50% of the iKO^{EC} mice, which resulted in both arteries and veins turning blue because of the formation of arteriovenous fistulae (Fig. 3E, iKO^{EC}, arrows). In addition, the

casted subcutaneous tissue in iKO^{EC} mice acquired a blue tint, indicating leakage of the casting agent from the vasculature (Fig. 3E). To validate this result, a Microfil of different gravity was used to cast iKO^{EC} and control mice. The casted subcutaneous tissue in iKO^{EC} mice turned yellow because of the leakage of Microfil from the vasculature (fig. S7A), consistent with the effect of the blue casting agent (Fig. 3E). Immunofluorescence staining of the skin showed that the abundance of the tight junction protein ZO-1 in endothelial cells was reduced in iKO^{EC} mice compared to control mice (fig. S6E), indicating the disruption of endothelial cell barriers in iKO^{EC} mice, which leads to vascular leakage. Together, these results demonstrate that endothelial cell-specific deletion of *Drosha* in mouse leads to multiple vascular defects, including tortuous and disorganized vasculature, vascular dilation, and AVMs, which mimic the phenotypes of the endothelial cell-specific *Alk1* or *Eng* gene knockout mice and the symptoms of human HHT patients.

Rare DROSHA variants are identified among HHT patients

Because of the similarities of the vascular lesions between *Drosha* cKO^{EC} and iKO^{EC} mice and human HHT patients, we hypothesized that patients with HHT without known causal mutations may carry an inactivating or hypomorphic mutant allele in the *DROSHA* gene. Thus, we performed exome sequencing in 23 affected individuals from 9 families and 75 probands suspected to have HHT who lacked mutations in known HHT genes (*ENG*, *ALK1*, *SMAD4*, or *BMP9*). The

Fig. 3. Postnatal depletion of Drosha in the endothelium in mice results in HHT-like vascular abnormalities. (A) Representative images of lungs from 10-week-old *Drosha* iKO^{EC} or Ctrl mice. White arrow, dilated capillary. $n = 4$ mice for each genotype. Scale bar, 1 mm. (B) Representative images of livers from 8-month-old *Drosha* iKO^{EC} or Ctrl mice. White arrow, dilated capillary. Scale bar, 1 mm. $n = 3$ mice for each genotype. (C) The diameter of lung and liver capillaries was quantified by ImageJ and presented as means $\pm$ SEM. * $P < 0.05$, significant by two-tailed unpaired Student's t test. (D) Representative images of intestines from 8-month-old *Drosha* iKO^{EC} or Ctrl mice and feces from 13-month-old *Drosha* iKO^{EC} or Ctrl mice. A, artery; V, vein. $n = 4$ Ctrl and 3 iKO^{EC} mice. Scale bar, 1 mm. (E) Representative images of the subcutaneous vasculature in the back of 8-month-old *Drosha* iKO^{EC} and Ctrl mouse $n = 4$ mice for each genotype. Scale bar, 500 μ m.

majority of individuals evaluated (74 of 98 individuals, 75.5%) had three or more clinical diagnostic criteria for HHT, and the remaining 24 individuals had two HHT clinical diagnostic criteria, typically epistaxis and telangiectasia. Consistent with our hypothesis, the exome data revealed an overrepresentation of rare missense variants in the *DROSHA* gene among individuals with HHT compared to the control population (Table 1). Three rare heterozygous, nonsynonymous substitutions (P32L, P100L, and K226E) were identified in the *DROSHA* gene in 7.14% (7 out of 98) of HHT patients, whereas they were present in only 0.04% of individuals in the regular population, a significantly lower percentage (Table 1). The P100L variant was found in one proband (Table 1, P4) and in four affected individuals of family 1 (F1-I-1,

F1-II-4, F1-III-1, and F1-III-2) spanning three generations (Fig. 4A). The other two variants (P32L and K226E) were found in two additional probands with HHT (P1 and P5 in Table 1). Clinical findings for each are listed in Table 1. All patients but one (P1) have epistaxis, most have telangiectasias, and several have solid organ AVMs. In addition, all these three rare variants were predicted to be “damaging” by at least one of the computational algorithms, such as SIFT (sorting intolerant from tolerant), PolyPhen-2, or Mutation Taster, which predict the effect of an amino acid substitution based on evolutionary conservation and structural impact. In particular, the Pro¹⁰⁰-to-Leu substitution was predicted to be damaging by all three computational algorithms (Table 1), and Pro¹⁰⁰ is conserved from human to zebrafish.

Table 1. Rare DROSHA variants identified in HHT patients. Sequencing was performed by Sanger sequencing. All nucleotide substitutions are heterozygous. F, family; P, proband; E, epistaxis; T, telangiectasia; GI-T, gastrointestinal telangiectasia; C, cerebral arteriovenous malformation (AVM); H, hepatic AVM; and P, pulmonary AVM. The presence of P32L (rs202053700; frequency, 0.0001), P100L (rs199846087; frequency, 0.0002), and K226E (rs762758438; frequency, 0.00009) was significantly lower in the Exome Aggregation Consortium (ExAC) database (which spans 60,706 unrelated individuals) compared to HHT patients using Fisher's exact test at $P < 0.01$. NA, not available.

Individual	Clinical description	Nucleotide change	Protein change	Presence in population*	Family segregation	Predicted effect	Other mutation
P1	P, mother with H, sister and grandmother have E	c.95C>T	p.P32L	0.0001	NA	Damaging [†]	None
F1-I-1	Severe E, (cauterized age 10)	c.299C>T	p.P100L	0.0002	Yes	Damaging [‡]	None
F1-II-4	Severe E, T	c.299C>T	p.P100L	0.0002	Yes	Damaging [‡]	None
F1-III-1	E, T	c.299C>T	p.P100L	0.0002	Yes	Damaging [‡]	None
F1-III-2	E, C (ruptured)	c.299C>T	p.P100L	0.0002	Yes	Damaging [‡]	None
P4	E, T	c.299C>T	p.P100L	0.0002	NA	Damaging [‡]	None
P5	E, T, P,	c.676A>G	p.K226E	0.00009	NA	Damaging [§]	None
F2-I-2	E, T, GI-T, P, H, liver shunts	c.836G>T	p.R279L	Absent	Yes	Damaging [¶]	ENG
F2-II-1	E, T, GI-T, multiple P	c.836G>T	p.R279L	Absent	Yes	Damaging [¶]	ENG

*Presence in population refers to the presence of the variant in the ExAC database. †Mutation is predicted to be damaging by SIFT. ‡Mutation is predicted to be damaging by SIFT, PolyPhen-2, and Mutation Taster. §Mutation is predicted to be damaging by Mutation Taster. ¶Mutation is predicted to be damaging by PolyPhen-2 and Mutation Taster. || Affected individuals in family 2 that carries a mosaic ENG c.1311+1G>A splice site mutation.

Thus, these three variants are likely to substantially change Drosha's structure and possibly its function. Because of the overrepresentation of missense variants in the *DROSHA* gene among individuals with HHT compared to the control population, it is plausible to speculate that these rare *DROSHA* variants might be linked to the development of vascular phenotypes of HHT.

In a separate HHT family (family 2) who carries a pathogenic splice site mutation in the *ENG* gene (c.1311+1G>A) (Table 1 and Fig. 4B), we found an additional *DROSHA* missense mutation in the Arg/Ser-rich domain, R279L, which was predicted to be damaging by two computational algorithms (PolyPhen-2 and Mutation Taster) (Table 1). The affected parent (F2-I-2) was mosaic for the *ENG* gene alleles because the mutation was detected in the hair bulb but not in the peripheral blood cells (Fig. 4B). Both affected individuals (F2-I-2 and F2-II-1) exhibited epistaxis of unusual frequency and duration for their age and multiple pulmonary AVMs that required treatment (Table 1), which is atypical for their ages. Furthermore, the parent (F2-I-2) exhibited hepatic involvement (Table 1). It is plausible to speculate that the R279L variant modifies the severity of the clinical manifestations mediated by the *ENG* gene alleles.

The N-terminal missense DROSHA mutants are partially inactive

All four variants identified in HHT patients were located in the N terminus of the *DROSHA* protein, which contains two evolutionarily conserved domains of unknown function, the Pro-rich domain (amino acids 1 to 212) and the Arg/Ser-rich domain (amino acids 219 to 316) (Fig. 4C). This region of the polypeptide has not been thoroughly studied, because the C terminus contains all the domains essential for Drosha's processing activity, such as two RNase III domains and the double-stranded RNA-binding domain (dsRBD) (Fig. 4C) (31). An N-terminal truncation mutant of Drosha, which lacks amino acids 1 to 390, shows significantly reduced processing activity compared to full-length Drosha when expressed at equivalent levels, indicating that

the N-terminal region (amino acids 1 to 390) of Drosha is required for the full activity of Drosha (32). In addition, the conservation of the Pro-rich and Arg/Ser-rich domains in Drosha among all vertebrates also supports the belief that the N terminus is functionally important.

To understand the function of the Pro-rich and Arg/Ser-rich N-terminal domains, mouse embryonic fibroblasts (MEFs) stably expressing human *DROSHA* wild type (WT) or variants (P100L and R279L) were subjected to miRNA expression analysis. The amount of all three *DROSHA* proteins (WT, P100L, or R279L) was similar (Fig. 5A). Exogenous expression of the WT *DROSHA* increased the abundance of miR-10a, miR-34a, miR-21, miR-103, and let-7a by 1.7-fold on average (Fig. 5B, mock compared to WT). In contrast, exogenous expression of P100L and R279L variants increased the abundance of these miRNAs only 1.4-fold and 1.1-fold, respectively. miR-126 abundance was unchanged because its processing does not require Drosha (Fig. 5B) (33). Next, an in vivo pri-miRNA processing assay was performed to assess *DROSHA* activity in nuclear extracts from MEFs stimulated with BMP4. The abundance of three *DROSHA* variants (WT, P100L, and R279L), pri-miR-21, and pri-miR-100 was similar (Fig. 5C). The amount of pre-miR-21 was induced 2.67-fold upon BMP4 treatment in WT cells; however, the abundance of pre-miR-21 in P100L and R279L cells was 1.66-fold and 1.44-fold, respectively (Fig. 5C). Consistent with this result, the *DROSHA* mutants produced less pre-miR-21 than WT *DROSHA* according to an in vitro processing assay (fig. S8A). Unlike miR-21, the amount of pre-miR-100, whose processing is independent of the BMP4-Smad pathway, was similar regardless of whether WT or the mutant *DROSHA* proteins were present (Fig. 5C). These results suggest that both variants are less active than WT Drosha and indicate an important function of the N-terminal Pro-rich and Arg/Ser-rich domain in the processing of pri-miRNAs.

Drosha activity is controlled by different cofactors, including the BMP signal transducers Smad1, Smad5, and Smad8 (Smad1/5/8). Upon BMP4 treatment, Smad1/5/8 are phosphorylated by the type I BMP

Fig. 4. HHT pedigrees with *DROSHA* nonsynonymous substitution alleles and a map of *DROSHA* variants. (A) The pedigree of family 1 carrying the *DROSHA* P100L variant. Circles and squares indicate females and males, respectively. Black symbols indicate individuals affected with HHT. The + sign indicates carriers of the rare *DROSHA* variant. (B) The pedigree of family 2 who carry the *DROSHA* R279L variant. Circles and squares indicate females and males, respectively. The + sign indicates carrier of the *DROSHA* variant and an *ENG* c.1311+1G>A mutation. The +’ sign indicates carrier of the *DROSHA* variant and mosaic carrier of an *ENG* c.1311+1G>A mutation. (C) Schematic representation of *DROSHA* protein and variants associated with HHT. Red circles indicate the position of variants and the number of HHT patients carrying the respective variant. dsRBD, double-stranded RNA-binding domain. Red ovals indicate the number of HHT patients carrying the respective variant. RNase, ribonuclease.

Fig. 5. The N-terminal missense mutants of *DROSHA* are partially inactive. (A) Drosha protein abundance in the nuclear extracts of mouse embryonic fibroblasts (MEFs) expressing *DROSHA* WT, P100L, R279L, or mock was analyzed by immunoblotting. Lamin A/C was used as a loading control. $n = 3$ independent experiments. (B) The abundance of different microRNAs (miRNAs) (miR-10a, miR-34a, miR-21, miR-103, let-7a, and miR-126) relative to U6 small nuclear RNA was quantitated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis in MEFs expressing *DROSHA* WT, P100L, R279L, or mock (empty vector) and shown as means $\pm$ SEM. $n = 3$ independent experiments. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, significant by one-way ANOVA with post hoc Tukey’s test. (C) In vivo miRNA processing assay. The nuclear extracts from MEFs expressing *DROSHA* WT, P100L, R279L, or mock were treated with or without BMP4 for 2 hours. Total RNA was extracted and subjected to qRT-PCR analysis of primary transcripts of miRNAs (pri-miRNA) and precursor miRNAs (pre-miRNA) of miR-21 and miR-100, and *DROSHA* mRNA was normalized to glyceraldehyde-3-phosphate dehydrogenase. RNA abundance relative to nontreated WT MEFs was plotted as means $\pm$ SD. $n = 3$ independent experiments. *** $P < 0.001$, significant by two-tailed unpaired Student’s t test.

receptor, translocate to the nucleus, and interact with Drosha in complex with RNA helicase p68 (also known as DDX5), which promotes the processing of a subset of miRNAs (3). After BMP4 stimulation, the amount of phosphorylated Smad1/5/8 was comparable between WT and P100L- or R279L-expressing MEFs (Fig. 6, input, p-Smad1/5/8). The amount of phosphorylated Smad1/5/8 was similar in the endothelial cells isolated from control or E13.5 *Drosha* cKO^{EC} embryos (fig. S8B). Similarly, BMP9 treatment induced similar amounts of phosphorylated SMAD1/5/8 in human microvascular endothelial cells (hMVECs) (fig. S8C), demonstrating that the *DROSHA* mutants did not affect the BMP-SMAD pathway. However, in MEFs, the amount of p68 and phosphorylated Smad1/5/8 that precipitated with the P100L and R279L mutants was decreased compared to WT *DROSHA*, despite similar immunoprecipitation efficiencies for all *DROSHA* pro-

teins (Fig. 6). These results suggest that the Pro-rich and Arg/Ser-rich domains in the N terminus of Drosha are required for the stable interaction with p68 and phosphorylated Smad1/5/8. We conclude that compared to WT *DROSHA*, P100L and R279L are less active enzymes in the processing of the BMP-Smad-dependent miRNAs.

Expression of the *DROSHA* mutants in zebrafish mimics the vascular phenotypes found in the *Drosha* morphants

To examine their in vivo activity, mRNAs encoding *DROSHA* mutants (P100L and R279L), WT or control (T7) RNA transcribed in vitro were injected into *Tg(flk1:egfp)*^{S843} embryos at the one- to two-cell stage. The morphology of the vasculature in P100L- and R279L-injected embryos was normal at 54 hpf (Fig. 7A, top). However, 45% of P100L and 37% of R279L mRNA-injected fish showed ISVs that failed to connect

Fig. 6. The N-terminal missense mutants of DROSHA show reduced binding activity with cofactors. The amount of Drosha cofactors (p68 and Smad1/5/8 associated with Drosha) was examined using nuclear extracts from MEFs stably expressing Flag-tagged WT, P100L, or R279L. Exogenously expressed DROSHA was immunoprecipitated by anti-Flag antibody. Immunoprecipitates were immunoblotted for p68, p-Smad1/5/8, or Drosha. Representative images are shown. $n = 3$ independent experiments.

to the DLAV [Fig. 7, A (white arrows) and B], similar to the *Droscha* morphants (Fig. 1A, white arrows). These results suggest that partially inactive DROSHA mutants interfere with endogenous Droscha in zebrafish. Unlike WT, the expression of P100L or R279L in *Droscha* morphants did not rescue the ISV phenotype (fig. S9, top right) or the vascular density of *Droscha* morphants (fig. S9, bottom right), demonstrating the compromised activity of the mutants. To examine the effect on vascular permeability, *DROSHA* (WT, P100L, or R279L) or control (T7) mRNA were injected into one- to two-cell stage *Tg(flk1:mcherry)* zebrafish in which endothelial cells are labeled by mCherry, and FITC-dextran was injected into the caudal plexus at 54 hpf. The ISVs and DAs in the *DROSHA* WT mRNA- or T7 RNA-injected zebrafish were demarcated by FITC-dextran and did not exhibit signs of vascular leakage (Fig. 7C). In contrast, in the zebrafish injected with Droscha mutants, the surface of the DA appeared rough (Fig. 7C, yellow arrows), a sign of FITC-dextran leakage, similar to the result of *Droscha* morphants (Fig. 1C, white arrows). These results demonstrate that exogenous expression of *DROSHA* missense mutants phenocopies angiogenesis defects mediated by the depletion of Droscha. Expression of these mutants impairs endothelial cell development and barrier function in vivo, underscoring an essential role of Droscha activity in vascular development and homeostasis in vertebrates. Although further genetic studies are necessary, our study suggests a potential link between *DROSHA* missense mutations and heritable vascular diseases such as HHT.

DISCUSSION

Our study demonstrated that Droscha was essential for normal endothelial development and promoted vascular development and homeostasis in vertebrates. It also sheds light on a potential involvement of

DROSHA dysfunction in human vascular disorders. On the basis of the overrepresentation of *DROSHA* variants in HHT patients that are rare among control populations, combined with analysis of these variants in vitro and in vivo, we speculate that these missense DROSHA mutants exhibit a substantially reduced activity that contribute to the development of vascular abnormalities similar to HHT. Somatic mutations in the C-terminal RNase III domains of DROSHA have been identified in Wilms tumors (34, 35). Rare *DROSHA* missense mutations enriched in patients with HHT were found in the N-terminal noncatalytic domains, demonstrating that the N-terminal region is indispensable for the full activity of DROSHA.

Endothelial-specific inactivation of *Eng* or *Alk1* in mice generates the most robust HHT animal models. *Alk1* endothelial-specific inactivation using the *L1-Cre* transgenic mouse (*Alk1^{fl/fl}; L1-cre*) shows tortuous, disorganized, enlarged vasculature; loss of microvessels; and AV shunts (30, 36). We pursued a similar approach in investigating the role of DROSHA in HHT etiology. Similar to the endothelial cell-specific *Alk1* knockout mouse, *Droscha* cKO^{EC} mice displayed an enlarged DA and disorganized and dilated hepatic and extraembryonic vasculature. *Droscha* iKO^{EC} mice showed loss of microvessels, enlarged capillaries, and AV shunts in the skin vasculature. Thus, endothelial-specific inactivation of *Droscha* has a damaging impact on endothelial cell development and homeostasis that partially resembles the effect of *Alk1* inactivation. However, *Alk1* endothelial cell-specific inactivation produces robust AVMs in the E16.5 yolk sac and in the GI and brain vasculature by P3 (30, 36). These features were not observed in *Droscha* cKO^{EC} or *Droscha* iKO^{EC} mice, suggesting that *Droscha* inactivation in the vascular endothelium causes HHT-like vascular defects that are partially distinct from those observed in *Alk1^{fl/fl}; L1-cre* mice. *Cdh5-cre* is expressed earlier in a broader range of tissues compared with *L1-cre*, which is driven by the *Alk1* promoter (30, 36), thus suggesting that the difference in cre-drivers might contribute to the differential vascular phenotype. Unlike *Alk1* (30, 36), endothelial-specific deletion of *Droscha* did not affect the BMP-Smad signaling pathway (fig. S8B). Therefore, it is likely that *DROSHA* mutations in endothelial cells have a different effect from that of *ALK1* or *ENG* mutations and that they alter the clinical spectrum or severity of HHT and possibly other vascular disorders. The co-occurrence of *DROSHA* and *ENG* mutant alleles in HHT family 2 (Fig. 3A) suggests that *DROSHA* mutant allele might lead to a more severe manifestation of HHT, possibly due to their combined effects on Smad-dependent transcriptional regulation (through *Eng*) and miRNA-dependent posttranscriptional regulation (through Droscha), resulting in broader alterations in the gene expression profile in vascular endothelium during developmental and postnatal angiogenesis.

It is intriguing that inactivation or missense mutations of ubiquitously expressed DROSHA mediated primarily vascular abnormalities in humans. Endothelial cells may be more sensitive to changes in the abundance of miRNAs than other tissues. For example, inactivation of endothelial cell-specific miR-126 is sufficient to cause ISV defects similar to those observed in *Droscha* morphants in zebrafish (33). However, miR-126 biogenesis is independent of Droscha (33), and the abundance of miR-126 is not affected in *Droscha* morphants or *Droscha* cKO^{EC} mice (27). Thus, future studies are necessary to identify endothelial cell-specific miRNAs that are essential for the vascular development and homeostasis. Upon identification of these miRNAs, it is possible that treatment with miRNA mimics or antagonists could ameliorate vascular lesions in patients with HHT or other vascular abnormalities.

Fig. 7. Exogenous expression of DROSHA missense mutants in zebrafish exhibits vascular phenotypes similar to *Droscha* morphants. (A) Control (T7) RNA and DROSHA WT, P100L, or R279L mRNA were injected into *Tg(flk1:egfp)^{sd43}*; *Tg(gata1:dsRed)^{sd2}* transgenic zebrafish at the one- to two-cell stage. Representative images of the whole zebrafish (top) and ISVs (bottom) at 54 hours postfertilization (hpf) are shown. $n = 36$ zebrafish for Ctrl, 30 zebrafish for WT, 28 zebrafish for P100L, and 33 zebrafish for R279L. Scale bar, 50 μm . (B) The fraction (%) of fish with ISV defects (top) and vascular density (bottom) are shown as means $\pm$ SEM. $*P < 0.05$, $**P < 0.01$, significant by one-way ANOVA with post hoc Tukey's test. (C) Control (T7) RNA and DROSHA WT, P100L, or R279L mRNA were injected into *Tg(flk1:mcherry)* zebrafish. At 54 hpf, angiography was performed, and representative images are shown (left). Mean fluorescence density was quantified by ImageJ and presented as means $\pm$ SEM (right). $n = 20$ zebrafish for Ctrl, 17 zebrafish for WT, 20 zebrafish for P100L, and 22 zebrafish for R279L. Scale bar, 200 μm . NS, not significant. $*P < 0.05$, $**P < 0.01$, significant by one-way ANOVA with post hoc Tukey's test.

MATERIALS AND METHODS

Ethical statement concerning the use of human subjects

The HHT exome cohort consisted of 23 affected individuals from 9 families and 75 additional probands for a total of 84 probands (In-

stitutional Review Board #00020480 at the University of Utah). The majority of the cohort was of Caucasian descent. All individuals were suspected to have HHT but harbored no mutations among the known genes associated with HHT. An additional HHT family 2, who carried a

novel variant of *DROSHA* and a mosaic mutation in the *ENG* gene, was also included, because these patients have more severe clinical symptoms than is normal. Informed consent was obtained from all individuals.

Mouse husbandry and handling

All animal experiments were conducted in compliance with University of California at San Francisco (UCSF) Laboratory Animal Research Committee guidelines and performed under the approved protocols (AN108100-03). *Cdh5-Cre* (26), *Drosha*^{tm1Littfloxed} lines (25), *Gt(ROSA)26Sor*^{tm4(ACTB-tdTomato,-EGFP)^{Luo}} lines (37), and *Cdh5-Cre/ERT2* (29) have been previously described. Embryos were dated by the presence of a vaginal plug in the female mouse at E0.5. Genomic DNA was generated from day 12 pups' tail tips or conceptus yolk sacs and genotyped with regular PCR. Primers were as follows: *Drosha*, 5'-GCAGAAAGTCTC-CCACTCCTAACCTTC-3' (forward) and 5'-CCAGGGGAAATTA-AACGAGACTCC-3' (reverse); *Cre*, 5'-TGCCACGACCAAGTGACAG-CA-3' (forward) and 5'-AGAGACGGAAATCCATCGCTC-3' (reverse).

Zebrafish husbandry and handling

Zebrafish (*D. rerio*) were maintained according to standard protocol (<http://zfin.org>) in compliance with local animal welfare regulations (AN151574). The following transgenic (Tg) zebrafish lines were used: Tg(flk1:mCherry), Tg(fli1:nEGFP)^{y7}, Tg(flk1:egfp)^{s843}, and Tg(flk1:GFP)^{s843}; Tg(gata1:dsRed)^{sd2} transgenic zebrafish (21, 38, 39). The culture was conducted in conformity with UCSF Institutional Animal Care and Use Committee and Association for Assessment and Accreditation of Laboratory Animal Care International guidelines.

Next-generation sequencing

Genomic DNA was extracted from peripheral blood using a Gentra Pure gene Blood Kit (Qiagen), and 3 µg was sheared to 180-bp fragments. Illumina adapters were added using the Bravo automated instrument and SureSelect XT kit reagents (Agilent Technologies). Adapter-ligated DNA underwent hybridization with biotinylated RNA baits designed to target the whole exome for 24 hours at 65°C. Hybridized DNA targets of interest were captured using streptavidin-coated magnetic beads and were eluted and barcoded/indexed after a series of washes to remove the nontargeted, unbound genome. DNA quality and quantity were assessed using the Bioanalyzer (Agilent Technologies), and samples were pooled and sequenced on a HiSeq2500 instrument (Illumina) using 2 × 100 paired-end sequencing. Sequences were aligned to the human genome reference (hg19) sequence using the Burrows-Wheeler Alignment tool (BWA 0.5.9) with default parameters (40). PCR duplicates were removed using the SAMtools package (41), and base quality score recalibration, local realignment, and variant calling were performed using the Genome Analysis Toolkit (GATK v1.3) (42). Variants with a less than 0.02% frequency in the general population were analyzed further. Ingenuity pathway analysis was used to identify biologically relevant gene variants (43). The prevalence of rare or previously unknown biologically relevant gene variation was compared to the prevalence in the control cohort to exclude genes that were not specific to the vascular HHT phenotype. Variants of interest were confirmed using Sanger sequencing. Primer sequences are available upon request.

Quantitation of miRNAs and in vitro pri-miRNA processing assay

Quantitative RT-PCR analysis of miRNAs and in vitro pri-miRNA processing assay were performed as previously reported (3, 44). MEFs were stimulated by BMP4 for 2 hours. Nuclear extracts were then

mixed with in vitro-transcribed pri-miR-21 (~100 nt) labeled with biotinylated uridine 5'-triphosphate, followed by the processing reaction and visualization of pri-miR-21 and the processing product pre-miR-21 (72 nt) by streptavidin staining.

Casting assay

The casting assay was performed as previously described (45, 46). Mice were anesthetized with 2% isoflurane and oxygen at 2 ml/min. The thoracic cavity was open, and the left ventricle was cannulated and perfused with 1× phosphate-buffered saline (PBS) at 80 mmHg. The right atrium was cut to allow outflow of PBS until all blood was washed out. Microfil casting agent (Flowtech Microfil MV-122 yellow or Flowtech Microfil MV-120 blue) was then perfused until vessels in the gut, stomach, brain, and liver were full. For lung casting, blood was cleared from the lungs by transecting the carotid artery. PBS (3 ml) was infused into the inferior vena cava. The Microfil casting agent was infused into the pulmonary artery by hand injection. After casting, mice were left for 90 min at room temperature or overnight at 4°C to cure. Organs were then dissected and dehydrated through a series of graded ethanol treatments and cleared in methyl salicylate for 12 to 24 hours.

Tamoxifen injection

Tamoxifen (Sigma-Aldrich T5648) was dissolved in corn oil at a concentration of 10 mg/ml. For adult *Drosha* iKO^{EC} mice analysis, 100 µg of tamoxifen was intraperitoneally injected into P2 and P4 pups. For miRNA and *Drosha* qPCR analysis, 2 mg of tamoxifen was injected into pregnant female mice on E11.5 and E13.5, and the livers of P1 pups were subjected to flow cytometry sorting for subsequent RNA preparation and qPCR analysis.

Whole-mount immunofluorescence staining

Yolk sacs were dissected at E13.5 and fixed in 4% paraformaldehyde solution overnight, dehydrated in a series of methanol/PBS washes, and stored at -20°C. The aorta-gonad-mesonephros (AGM) was rehydrated through a series of graded methanol/PBS washes, blocked at 3% milk with 0.1% Tween-20 in PBS for 2 hours at room temperature, and then incubated with primary antibody for 48 hours at 4°C. AGMs were then washed with 3% milk with 0.1% Tween 20 in PBS five times, 1 hour each time, and the last wash was overnight at 4°C. Secondary antibody was incubated for 48 hours at 4°C. AGMs were then dehydrated through methanol/PBS washes, cleared, and mounted with benzyl alcohol/benzyl benzoate. Images were taken with a Leica SPE confocal microscope and compiled with ImageJ software. The following antibodies directed against mouse antigens were used: CD31 (BD Pharmaceuticals, 550274) and anti-rat 594 (Thermo Fisher Scientific, A-21209).

Cryostat and immunofluorescence staining

Livers from E13.5 mice or guts from adult mice were dissected and fixed in 4% paraformaldehyde solution overnight, dehydrated with 30% sucrose in PBS until tissues sunk to the bottom of the tube. Tissues were then embedded in Tissue-Tek OCT compound (Sakura Finetek, 4583). Cryosections (40 µm) were done with Leica CM1850V. Slides were dried for 2 hours at room temperature and stored at -80°C before immunofluorescence staining. Cryosections were warmed to room temperature, washed in PBS, permeabilized in 0.5% Triton X-100 in PBS for 10 min and blocked in 3% bovine serum albumin (BSA) and 0.05% Triton X-100 in PBS for 1 hour at room temperature. Slides were incubated with primary antibodies at 4°C overnight, followed by PBS

wash and secondary antibody incubation for 1 to 2 hours at room temperature. Images were taken with Leica SPE confocal microscope and compiled with ImageJ software.

Histology

E14.5 embryos were harvested by cesarean section, rinsed in PBS (pH 7.4), fixed in 4% paraformaldehyde overnight at 4°C, embedded in paraffin, sectioned at a thickness of 7 μ m, and stained with H&E.

β -Galactosidase staining

E12.5 embryos were dissected and fixed in 4% fixative (2% formaldehyde, 0.02% NP-40, 0.2% glutaraldehyde, 5 mM EDTA, and 2 mM magnesium chloride in PBS) for 1 hour at room temperature, washed in PBST (0.1% Triton X-100 and 2 mM magnesium chloride in PBS), and then stained in staining solution (2 mM magnesium chloride, 0.01% sodium deoxycholate, 0.02% NP-40, 5 mM potassium ferricyanide crystalline, 5 mM potassium ferricyanide trihydrate, and 1 mg/ml X-Gal in PBS) at 37°C for 3 to 5 hours. The DA was subsequently dissected for imaging.

Flow analysis of EdU incorporation

The rate of cell proliferation *in vivo* was measured by EdU incorporation into DNA followed by the Click-iT EdU Alexa Flour 488 Flow Cytometry Assay Kit (Invitrogen/Molecular Probes C10425). E10.5 pregnant female mice were injected with EdU (50 mg/kg) 1 hour before euthanization, and embryos were harvested in fluorescence-activated cell sorting (FACS) buffer. AGMs were pipetted into single-cell suspensions, washed with PBS, and stained with fixable viability dye eFluor 450 (eBioscience, 65-0863-14). Cells were then fixed, permeabilized, and stained with Click-iT EdU reaction cocktail, followed by wash and cell surface marker staining and flow analysis.

Stable expression of DROSHA WT or mutant in MEFs

Flag-tagged *DROSHA* WT, P100L, or R279L was subcloned into the pBABE-puro plasmid. To produce virus, Bosc23 cells were co-transfected with the pBABE-*DROSHA* WT, P100L, or R279L expression constructs and the ecotropic packaging vector pCL-L at 3:1 ratio using Lipofectamine 2000 (11668027, Invitrogen) according to the manufacturer's instructions. Medium was collected 48 hours later, filtered with a 0.45- μ m filter and buffered with 10 mM Hepes (pH 7.5). MEFs were infected with a 1:5 dilution of virally conditioned medium at 50% confluence with polybrene (2 μ g/ml). After 2 days of culture, MEFs were subsequently split and selected with puromycin (2.5 μ g/ml).

Analysis of primary endothelial cells

E13.5 livers were harvested in FACS buffer, pipetted into single-cell suspension, and stained with CD31 and CD45 for 1.5 hours at 4°C. Endothelial cells (CD31⁺CD45⁻) were then sorted by a BD FACS Aria III Cell Sorter. Cells from E13.5 livers of four embryos of the same genotype were pooled and lysed in lysis buffer (10 mM tris-HCl, 1% SDS, and 0.2 mM phenylmethylsulfonyl fluoride) supplemented with phosphatase inhibitor (Roche, PhosSTOP, 04906837001) and protease inhibitor (Roche, complete mini EDTA free, 04693159001). Samples were then boiled at 95°C for 10 min and centrifuged at 10,000g for 30 min. The supernatants were subjected to Western blot. For miRNA and *Drosha* qPCR analysis, 2 mg of tamoxifen was injected into pregnant female mice on E11.5 and E13.5. P1 liver was harvested and sorted as described above. Endothelial cells were sorted into Trizol LS (Invitrogen,

10296010), and total RNA was prepared and subjected to miRNA qRT-PCR analysis.

hMVEC culture, adenovirus infection, and BMP9 treatment

hMVECs were cultured in EGM-2 MV BulletKit medium (Lonza, CC-4147) in 5% CO₂ at 37°C. Adenoviruses encoding *DROSHA* WT and mutants were produced with AdEasy Adenoviral Vector System (Agilent Technologies). Complementary DNA (cDNA) of human *DROSHA* WT, P100L, or R279L was cloned into pShuttle-CMV vector. Adenovirus was then produced following the manufacturer's manual and amplified with ade-293 cell lines. Infection of MVECs at ~80% confluence was carried out at 37°C and 5% CO₂ at a multiplicity of infection of 50 for 6 hours. Infected MVECs were cultured overnight in fresh medium. Infection of MVECs was carried out again on the next day for 6 hours before cells were treated with BMP9 and then lysed for nuclear extract. For BMP9 treatment, BMP9 or vehicle (0.1% BSA in 4 mM HCl) was added into basal EGM-2 medium at a final concentration of 1 nM for 2 hours at 37°C and 5% CO₂.

MO and mRNA injection

For *Drosha* morphant analysis, MO1 (5'-TCCACGGCCAGCATG-GAAAGACATC-3') or MO2 (5'-AGAGGTGAAGCACATTACCT-GCTGC-3') was synthesized by Gene Tools, LLC. One nanogram of *Drosha*MO1 (which targeted translation initiation) or *Drosha*MO2 (which targeted mRNA splicing) was injected into the fertilized egg of *Tg(flk1:GFP)^{s843};Tg(gata1:dsRed)^{sd2}* transgenic zebrafish within 45 min after fertilization. The endothelial cells are labeled with EGFP, and hematopoietic cells are labeled with dsRed in this zebrafish line. For angiography analysis, 1 ng of MO1 and 1 ng of MO2 were combined and injected into *Tg(flk1:mCherry)* transgenic zebrafish within 45 min after fertilization. The endothelial cells are labeled with mCherry in this zebrafish line. For mRNA expression, human *DROSHA* WT, P100L, and R279L mutant cDNAs were cloned into pcDNA3.1 vector and *in vitro*-transcribed with the mMACHINE T7 Transcription Kit (Ambion, AM1344). Human *DROSHA* mRNA is resistant to MO1 and MO2. One hundred picograms of control T7 or *DROSHA* WT, P100L, or R279L mRNA was injected into *Tg(flk1:GFP)^{s843};Tg(gata1:dsRed)^{sd2}* transgenic zebrafish at the one- to two-cell stage. For MO rescue, 1 ng of MO1 + 1 ng of MO2 + 100 pg of control T7 mRNA or *DROSHA* WT mRNA were mixed and injected into *Tg(flk1:GFP)^{s843};Tg(gata1:dsRed)^{sd2}* transgenic zebrafish at the one- to two-cell stage. At 54 hpf, the vasculature of zebrafish was analyzed. Images were taken with a Leica SPE confocal microscope and compiled with ImageJ software. Images were taken with a Leica SPE confocal microscope and compiled with ImageJ software.

Angiography

Polymer microspheres (Thermo Fisher Scientific, 3020A) or FITC-conjugated dextran (2,000,000 molecular weight, ~10-nm diameter; Molecular Probes, D7137) was diluted in PBS (1:10) and injected into the caudal plexus of 54-hpf *flk:mCherry* transgenic zebrafish. Zebrafish injected with dextran were imaged 20 min after the injection, and zebrafish injected with microspheres were imaged 2 hours after the injection with a Leica SPE confocal microscope and images were compiled with ImageJ software.

Stool guaiac test

Hemocult SENSa and Hemocult II SENSa (Beckman Coulter Inc.) were used to detect the presence of occult blood in the feces of *Drosha*

iKO mice or littermate controls. Some modifications were made to the manual to test fecal samples from mice: 15 μ l of PBS was injected into feces to soften it. Five pieces of softened feces from each mouse were then pooled, smeared, and applied into the sample box. Five minutes later, two drops of Hemocult SENA Developer was applied to guaiac paper directly over the smear.

Image quantitation

Vascular density was calculated as the percentage of endothelial cell area in total area. For ISV vascular density, the area between four continuous ISV was calculated as the total area, and the area of vessels within the total area (four ISVs) was calculated as the endothelial cell area. For craniofacial vascular density, the area between the middle cerebral vein, the primordial hindbrain channel, and the posterior cerebral vein was calculated as the total area, and the area of all the vessels within the total area was calculated as the endothelial cell area. All the area calculations were carried out by ImageJ software. Mean fluorescence density was quantitated by ImageJ. Quantification of ISV defects was calculated as the percentage of fish with ISV defects in the total fish.

Statistical analysis

A Fisher's exact test was used to determine the statistical significance of the prevalence of rare DROSHA variants in the HHT compared to the Exome Aggregation Consortium database. Statistical analysis was performed using the Prism 5.01 GraphPad package. Statistical tests and significance are denoted in the figure legends.

SUPPLEMENTARY MATERIALS

www.sciencesignaling.org/cgi/content/full/11/513/eaan6831/DC1

- Fig. S1. *Drosha* morphants develop angiogenesis defects.
- Fig. S2. Generating *Drosha* mutant fish by CRISPR/Cas9.
- Fig. S3. *Drosha* morphants showed vascular leakiness.
- Fig. S4. *Drosha* cKO^{EC} embryos showed mild angiogenesis defects and a sign of hemorrhage.
- Fig. S5. *Drosha* cKO^{EC} embryos showed disorganized and dilated vasculature.
- Fig. S6. *Drosha* iKO^{EC} mice show vascular leakage.
- Fig. S7. The distribution of the tight junction protein ZO-1 is disrupted in the endothelial cells of *Drosha* iKO^{EC} mice.
- Fig. S8. In vitro processing assay of pri-miR-21 and the BMP-Smad signaling pathway in cells expressing DROSHA mutants or depleted of *Drosha*.
- Fig. S9. ISV defects mediated by the knockdown of *Drosha* by morpholino oligos are rescued by coinjection of wild-type (WT) *Drosha* mRNA, but not by mutant mRNA.

REFERENCES AND NOTES

1. M.-J. Goumans, A. Zwijsen, P. ten Dijke, S. Bailly, Bone morphogenetic proteins in vascular homeostasis and disease. *Cold Spring Harb. Perspect. Biol.* a031989 (2017).
2. A. Hata, Y.-G. Chen, TGF- β signaling from receptors to Smads. *Cold Spring Harb. Perspect. Biol.* 8, a022061 (2016).
3. B. N. Davis, A. C. Hilyard, G. Lagna, A. Hata, SMAD proteins control DROSHA-mediated microRNA maturation. *Nature* 454, 56–61 (2008).
4. M. Ha, V. N. Kim, Regulation of microRNA biogenesis. *Nat. Rev. Mol. Cell Biol.* 15, 509–524 (2014).
5. Y. Lee, C. Ahn, J. Han, H. Choi, J. Kim, J. Yim, J. Lee, P. Provost, O. Rådmark, S. Kim, V. N. Kim, The nuclear RNase III Drosha initiates microRNA processing. *Nature* 425, 415–419 (2003).
6. E. Berezikov, W.-J. Chung, J. Willis, E. Cuppen, E. C. Lai, Mammalian mirtron genes. *Mol. Cell* 28, 328–336 (2007).
7. J. G. Ruby, C. H. Jan, D. P. Bartel, Intronic microRNA precursors that bypass Drosha processing. *Nature* 448, 83–86 (2007).
8. L. Castellano, J. Stebbing, Deep sequencing of small RNAs identifies canonical and non-canonical miRNA and endogenous siRNAs in mammalian somatic tissues. *Nucleic Acids Res.* 41, 3339–3351 (2013).
9. M. Xie, M. Li, A. Vilborg, N. Lee, M.-D. Shu, V. Yartseva, N. Šestan, J. A. Steitz, Mammalian 5'-capped microRNA precursors that generate a single microRNA. *Cell* 155, 1568–1580 (2013).
10. M. Yoda, D. Cifuentes, N. Izumi, Y. Sakaguchi, T. Suzuki, A. J. Giraldez, Y. Tomari, Poly(A)-specific ribonuclease mediates 3'-end trimming of Argonaute2-cleaved precursor microRNAs. *Cell Rep.* 5, 715–726 (2013).
11. J. Han, J. S. Pedersen, S. C. Kwon, C. D. Belair, Y.-K. Kim, K.-H. Yeom, W.-Y. Yang, D. Haussler, R. Billewicz, V. N. Kim, Posttranscriptional crossregulation between Drosha and DGCR8. *Cell* 136, 75–84 (2009).
12. C. Rolando, A. Erni, A. Grison, R. Beattie, A. Engler, P. J. Gokhale, M. Milo, T. Wegleiter, S. Jessberger, V. Taylor, Multipotency of adult Hippocampal NSCs in vivo is restricted by Drosha/NFIB. *Cell Stem Cell* 19, 653–662 (2016).
13. N. Gromak, M. Dienstbier, S. Macias, M. Plass, E. Eyras, J. F. Cáceres, N. J. Proudfoot, Drosha regulates gene expression independently of RNA cleavage function. *Cell Rep.* 5, 1499–1510 (2013).
14. J. Richards-Yutz, K. Grant, E. C. Chao, S. E. Walther, A. Ganguly, Update on molecular diagnosis of hereditary hemorrhagic telangiectasia. *Hum. Genet.* 128, 61–77 (2010).
15. J. McDonald, P. Bayrak-Toydemir, R. E. Pyeritz, Hereditary hemorrhagic telangiectasia: An overview of diagnosis, management, and pathogenesis. *Genet. Med.* 13, 607–616 (2011).
16. M. Mahmoud, P. D. Upton, H. M. Arthur, Angiogenesis regulation by TGF β signalling: Clues from an inherited vascular disease. *Biochem. Soc. Trans.* 39, 1659–1666 (2011).
17. J. McDonald, W. Wooderchak-Donahue, C. VanSant Webb, K. Whitehead, D. A. Stevenson, P. Bayrak-Toydemir, Hereditary hemorrhagic telangiectasia: Genetics and molecular diagnostics in a new era. *Front. Genet.* 6, 1 (2015).
18. S. A. Abdalla, M. Letarte, Hereditary haemorrhagic telangiectasia: Current views on genetics and mechanisms of disease. *J. Med. Genet.* 43, 97–110 (2006).
19. S. Dupuis-Girod, S. Bailly, H. Plauchu, Hereditary hemorrhagic telangiectasia: From molecular biology to patient care. *J. Thromb. Haemost.* 8, 1447–1456 (2010).
20. H. Neuhaus, V. Rosen, R. S. Thies, Heart specific expression of mouse *BMP-10* a novel member of the TGF- β superfamily. *Mech. Dev.* 80, 181–184 (1999).
21. B. L. Roman, V. N. Pham, N. D. Lawson, M. Kulik, S. Childs, A. C. Lekven, D. M. Garrity, R. T. Moon, M. C. Fishman, R. J. Lechleider, B. M. Weinstein, Disruption of *acvrl1* increases endothelial cell number in zebrafish cranial vessels. *Development* 129, 3009–3019 (2002).
22. E. Wienholds, M. J. Koudijs, F. J. M. van Eeden, E. Cuppen, R. H. A. Plasterk, The microRNA-producing enzyme Dicer1 is essential for zebrafish development. *Nat. Genet.* 35, 217–218 (2003).
23. D. Y. R. Stainier, E. Raz, N. D. Lawson, S. C. Ekker, R. D. Burdine, J. S. Eisen, P. W. Ingham, S. Schulte-Merker, D. Yelon, B. M. Weinstein, M. C. Mullins, S. W. Wilson, L. Ramakrishnan, S. L. Amacher, S. C. F. Neuhauss, A. Meng, N. Mochizuki, P. Panula, C. B. Moens, Guidelines for morpholino use in zebrafish. *PLOS Genet.* 13, e1007000 (2017).
24. A. J. Giraldez, R. M. Cinalli, M. E. Glasner, A. J. Enright, J. M. Thomson, S. Baskerville, S. M. Hammond, D. P. Bartel, A. F. Schier, MicroRNAs regulate brain morphogenesis in zebrafish. *Science* 308, 833–838 (2005).
25. M. M. W. Chong, J. P. Rasmussen, A. Y. Rudensky, D. R. Littman, The RNaseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. *J. Exp. Med.* 205, 2005–2017 (2008).
26. M. J. Chen, T. Yokomizo, B. M. Zeigler, E. Dzierzak, N. A. Speck, Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. *Nature* 457, 887–891 (2009).
27. X. Jiang, J. S. Hawkins, J. Lee, C. O. Lizama, F. L. Bos, J. P. Zape, P. Ghatpande, Y. Peng, J. Louie, G. Lagna, A. C. Zovein, A. Hata, Let-7 microRNA-dependent control of leukotriene signaling regulates the transition of hematopoietic niche in mice. *Nat. Commun.* 8, 128 (2017).
28. O. Tornavaca, M. Chia, N. Dufton, L. O. Almagro, D. E. Conway, A. M. Randi, M. A. Schwartz, K. Matter, M. S. Balda, ZO-1 controls endothelial adherens junctions, cell–cell tension, angiogenesis, and barrier formation. *J. Cell Biol.* 208, 821–838 (2015).
29. I. Sörensen, R. H. Adams, A. Gossler, DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries. *Blood* 113, 5680–5688 (2009).
30. S. O. Park, M. Wankhede, Y. J. Lee, E.-J. Choi, N. Fliess, S.-W. Choe, S.-H. Oh, G. Walter, M. K. Raizada, B. S. Sorg, S. P. Oh, Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. *J. Clin. Invest.* 119, 3487–3496 (2009).
31. K.-H. Yeom, Y. Lee, J. Han, M. R. Suh, V. N. Kim, Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing. *Nucleic Acids Res.* 34, 4622–4629 (2006).
32. J. Han, Y. Lee, K.-H. Yeom, Y.-K. Kim, H. Jin, and V. N. Kim, The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev.* 18, 3016–3027 (2004).
33. J. E. Fish, M. M. Santoro, S. U. Morton, S. Yu, R.-F. Yeh, J. D. Wythe, K. N. Ivey, B. G. Bruneau, D. Y. R. Stainier, D. Srivastava, miR-126 regulates angiogenic signaling and vascular integrity. *Dev. Cell* 15, 272–284 (2008).
34. D. Rakheja, K. S. Chen, Y. Liu, A. A. Shukla, V. Schmidt, T.-C. Chang, S. Khokhar, J. E. Wickiser, N. J. Karandikar, J. S. Malter, J. T. Mendell, J. F. Amatruda, Somatic mutations in DROSHA

- and *DICER1* impair microRNA biogenesis through distinct mechanisms in Wilms tumours. *Nat. Commun.* **2**, 4802 (2014).
35. G. T. Torrezan, E. N. Ferreira, A. M. Nakahata, B. D. F. Barros, M. T. M. Castro, B. R. Correa, A. C. V. Krepsich, E. H. R. Olivieri, I. W. Cunha, U. Tabori, P. E. Grundy, C. M. L. Costa, B. de Camargo, P. A. F. Galante, D. M. Carraro, Recurrent somatic mutation in *DROSHA* induces microRNA profile changes in Wilms tumour. *Nat. Commun.* **5**, 4039 (2014).
 36. S. O. Park, Y. J. Lee, T. Seki, K.-H. Hong, N. Fliess, Z. Jiang, A. Park, X. Wu, V. Kaartinen, B. L. Roman, S. P. Oh, ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. *Blood* **111**, 633–642 (2008).
 37. M. D. Muzumdar, B. Tasic, K. Miyamichi, L. Li, L. Luo, A global double-fluorescent Cre reporter mouse. *Genesis* **45**, 593–605 (2007).
 38. K. Proulx, A. Lu, S. Sumanas, Cranial vasculature in zebrafish forms by angioblast cluster-derived angiogenesis. *Dev. Biol.* **348**, 34–46 (2010).
 39. S.-W. Jin, W. Herzog, M. M. Santoro, T. S. Mitchell, J. Frantsve, B. Jungblut, D. Beis, I. C. Scott, L. A. D'Amico, E. A. Ober, H. Verkade, H. A. Field, N. C. Chi, A. M. Wehman, H. Baier, D. Y. R. Stainier, A transgene-assisted genetic screen identifies essential regulators of vascular development in vertebrate embryos. *Dev. Biol.* **307**, 29–42 (2007).
 40. H. Li, R. Durbin, Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).
 41. H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis, R. Durbin; 1000 Genome Project Data Processing Subgroup, The sequence alignment/map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
 42. A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytzky, K. Garimella, D. Altshuler, S. Gabriel, M. Daly, M. A. DePristo, The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* **20**, 1297–1303 (2010).
 43. A. Kramer, J. Green, J. Pollard Jr., S. Tugendreich, Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics* **30**, 523–530 (2014).
 44. B. N. Davis, A. C. Hilyard, P. H. Nguyen, G. Lagna, A. Hata, Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. *Mol. Cell* **39**, 373–384 (2010).
 45. H. Cuervo, C. M. Nielsen, D. A. Simonetto, L. Ferrell, V. H. Shah, R. A. Wang, Endothelial notch signaling is essential to prevent hepatic vascular malformations in mice. *Hepatology* **64**, 1302–1316 (2016).
 46. D. Miniati, E. B. Jelin, J. Ng, J. Wu, T. R. Carlson, X. Wu, M. R. Looney, R. A. Wang, Constitutively active endothelial Notch4 causes lung arteriovenous shunts in mice. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **298**, L169–L177 (2010).

Acknowledgments: We thank R. Wang and C. Nielsen (UCSF) for assisting in vasculature casting. We also thank R. Adams (Max Planck Institute) for the *Cdh5-CreERT2* mouse, N. Speck (University of Pennsylvania) for the *Cdh5-Cre* mouse, and S. Sumanas (University of Cincinnati College of Medicine), D. Stanier (Max Planck Institute), and B. Weinstein (Eunice Kennedy Shriver National Institute of Child Health and Human Development) for the *Tg(flk1:mCherry)*, *Tg(flk1:egfp)^{s843}*, and *Tg(gata1:dsRed)^{sd2}* transgenic zebrafish line, respectively. Finally, we thank all members of the Hata laboratory, in particular Y. Peng for technical support. **Funding:** This work was supported by grants from the NIH (HL116191 and HL132058) and the LeDucq foundation to A.H. and the ARUP Institute for Clinical and Experimental Pathology to P.B.-T. **Author contributions:** X.J., W.L.W.-D., J.M., P.B.-T., G.L., and A.H. designed, performed, and analyzed most experiments, conceived the project, and drafted the manuscript. P.G. assisted with the genotyping of mice. M.B., M.S., and D.H. designed, performed, and analyzed zebrafish MO injections. H.C. and S.C. designed, performed, and analyzed angiography in zebrafish. **Data and materials availability:** *Drosha* knockout mouse and zebrafish lines will be available upon completion of a Material Transfer Agreement with UCSF. **Competing interests:** The authors declare that they have no competing interests.

Submitted 18 May 2017

Accepted 12 December 2017

Published 16 January 2018

10.1126/scisignal.aan6831

Citation: X. Jiang, W. L. Wooderchak-Donahue, J. McDonald, P. Ghatpande, M. Baalbaki, M. Sandoval, D. Hart, H. Clay, S. Coughlin, G. Lagna, P. Bayrak-Toydemir, A. Hata, Inactivating mutations in Drosha mediate vascular abnormalities similar to hereditary hemorrhagic telangiectasia. *Sci. Signal.* **11**, eaan6831 (2018).

Inactivating mutations in Drosha mediate vascular abnormalities similar to hereditary hemorrhagic telangiectasia

Xuan Jiang, Whitney L. Wooderchak-Donahue, Jamie McDonald, Prajakta Ghatpande, Mai Baalbaki, Melissa Sandoval, Daniel Hart, Hilary Clay, Shaun Coughlin, Giorgio Lagna, Pinar Bayrak-Toydemir and Akiko Hata

Sci. Signal. **11** (513), ean6831.
DOI: 10.1126/scisignal.aan6831

Processing microRNAs for blood vessels

Individuals with hereditary hemorrhagic telangiectasia (HHT) form direct and fragile connections between arteries and veins that are prone to rupture. Most HHT patients have mutations in components of the transforming growth factor- β and bone morphogenetic protein signaling pathways, which regulate blood vessel formation. Noting that the microRNA processing enzyme Drosha interacts with effector proteins in these pathways, Jiang *et al.* showed that Drosha-deficient zebrafish and mice with an endothelial cell-specific ablation of Drosha had vascular defects reminiscent of those found in HHT patients. Rare mutations in *DROSHA* were overrepresented in HHT patients who lacked the typical disease-associated mutations. Two of these mutants showed reduced activity and could not rescue the vascular phenotypes of *Drosha*-deficient zebrafish. Because the mutations in humans and zebrafish were global and not specific to endothelial cells, the predominantly vascular phenotypes suggest that endothelial cells are particularly sensitive to changes in microRNA abundance.

ARTICLE TOOLS

<http://stke.sciencemag.org/content/11/513/ean6831>

SUPPLEMENTARY MATERIALS

<http://stke.sciencemag.org/content/suppl/2018/01/11/11.513.ean6831.DC1>

RELATED CONTENT

<http://stke.sciencemag.org/content/sigtrans/10/499/eaal2987.full>
<http://stke.sciencemag.org/content/sigtrans/10/479/eaam5711.full>
<http://stke.sciencemag.org/content/sigtrans/9/437/ra72.full>
<http://science.sciencemag.org/content/sci/358/6361/321.full>
<http://stm.sciencemag.org/content/scitransmed/8/362/362ra144.full>

REFERENCES

This article cites 45 articles, 10 of which you can access for free
<http://stke.sciencemag.org/content/11/513/ean6831#BIBL>

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)